BioAdvance News

Melior Pharmaceuticals Initiates Phase 2b Study with MLR-1023 for Type 2 Diabetes

By WebmasterOctober 3, 2017November 1st, 2024No Comments

Melior Pharmaceuticals Initiates Phase 2b Study with MLR-1023 for Type 2 Diabetes

Previous PostRelmada Therapeutics Announces $6.9 Million Private Placement
Next PostOpsidio Closes Bridge Financing to Develop Monoclonal Antibodies to Treat Fibrotic Diseases